In focus · trending topic

Crinetics

8 stories · following the connections

Crinetics Pharmaceuticals Completes $63.5 Million Series B Financing

By Nasdaq OMXMar 13, 2018, 6:00 PM UTC

Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018

By Nasdaq OMXMar 12, 2018, 8:06 PM UTC

Crinetics Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference

By Nasdaq OMXMar 7, 2018, 9:06 PM UTC

Crinetics Pharmaceuticals Appoints Marc Wilson as Chief Financial Officer

By Nasdaq OMXJan 4, 2018, 2:01 PM UTC

Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

By Nasdaq OMXJan 2, 2018, 2:01 PM UTC

Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly

By Nasdaq OMXOct 26, 2017, 2:30 PM UTC

Crinetics Pharmaceuticals Awarded Two SBIR Grants to Develop New Therapeutics for Congenital Hyperinsulinism and Cushing’s Disease

By Nasdaq OMXSep 6, 2017, 1:01 PM UTC

Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808

By Nasdaq OMXJul 13, 2017, 5:00 PM UTC